BMW shares slumped on Tuesday, falling 7%, after the German automaker said volumes in China were below expectations and that the U.S.-European Union tariff agreement has yet to materialize. ...

投资评级与目标价 - 高盛将Bunzl plc的投资评级从卖出上调至中性 主要基于股价大幅下跌后风险回报状况更为平衡 [1] - 高盛设定Bunzl未来12个月的目标股价为2510便士 意味着较当前水平有约5%的上涨空间 [1] 股价表现与业绩预警 - Bunzl公司股价在2025年已下跌约30% 主要受4月份发布的盈利预警拖累 该预警下调了明年的增长和利润率预期 [2] - 盈利预警部分归因于北美业务的疲软 该地区业务贡献集团约60%的营收 [2] 近期业绩与财务措施 - Bunzl上半年的业绩基本符合预期 同时公司已恢复股票回购计划 这缓解了部分近期盈利和杠杆风险 [3] - 高盛目前预计Bunzl的2025年EBITA利润率为7.6% 低于2024年的8% 但认为后续年份有逐步改善的空间 [3] 估值水平与业务模式 - 按当前股价计算 Bunzl的估值约为高盛预估的2026年收益的13倍 低于其历史周期中期平均倍数17倍 [4] - 估值折价加上Bunzl具有韧性的业务模式 使得公司股票风险低于今年早些时候 [4]

By Louise Rasmussen, Jacob Gronholt-Pedersen and Maggie Fick COPENHAGEN (Reuters) - Novo Nordisk, the maker of blockbuster weight-loss drug Wegovy, said on Wednesday it will cut 9,000 jobs in a bid to reignite growth and fend off intense competition from U.S. rival Eli Lilly and a wave of compounded copycat drugs. The restructuring, including the largest layoff in Denmark's history, is expected to save 8 billion Danish crowns ($1.25 billion) annually and comes as Novo Nordisk is battling to revive its fo ...